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EDITORIALTesting for COVID-19 in lung cancer patientsCoronavirus disease 2019 (COVID-19) is a respiratory tract
infection caused by the severe acute respiratory syndrome
(SARS) coronavirus (COV), also named SARS-CoV-2. COVID-
19 was first recognized in Central China (Wuhan, the capital
of Hubei province) at the end of December 2019, later
becoming a pandemic, spreading rapidly in multiple coun-
tries worldwide.1 According to data from China and Italy,
the first two countries with the highest incidence, the ma-
jority of patients infected by SARS-CoV-2 were asymptom-
atic or presented with mild upper respiratory tract
symptoms. However, about 14%e24% of patients devel-
oped pneumonitis and required hospitalization and oxygen
support. About 5% of patients developed acute respiratory
distress syndrome (ARDS) or sepsis-related acute organ
dysfunction, requiring admission to intensive care units.2,3
The case fatality rate (CFR ¼ %), defined as the number
of deaths in COVID-19-positive patients divided by the
number of those who tested positive, is significantly higher
for those with underlying concomitant disease, such as
cardiovascular disease, diabetes, chronic respiratory disease
and cancer, as well as older age. This phenomenon is
observed in both Chinese and Italian populations, but it
appears to be more pronounced in the Caucasian popula-
tion.3,4 The overall CFR in China was reported at 2.3%
compared with 7.2% in Italy. A stratified analysis showed
that the CFR in Italy and China was very similar in patients
who are younger (<70 years), but higher in Italy for patients
who are 70 years or above. This includes 687 patients who
were older than 90 years, where the CFR was 37.6% and
11.9% in Italy and China, respectively.
Different approaches towards SARS-CoV-2 testing could
partly explain the difference in incidence and CFR. Initially,
Italy adopted a non-discriminative testing strategy that
included both symptomatic and asymptomatic patients. But
after 6 days, when large numbers of patients suffered from
severe SARS-CoV-2-related ARDS, the Italian Ministry of
Health decided to allow testing only in symptomatic pa-
tients who were potential candidates for hospitalization,
and this decision may have resulted in a biased selection
and delayed treatment of these patients. In this editorial,
we would like stress the identification of lung cancer
patients as a specific population for testing prioritization
for COVID-19.
Based on the available data, smoking history has been
correlated with a higher incidence and severity of SARS-
CoV-2 infection.4,5 Comparing smokers and non-smokers,
the risk of severe symptoms is 1.4 times higher0923-7534/© 2020 European Society for Medical Oncology. Published by
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832(RR ¼ 1.4, 95% CI: 0.98e2.00), and the risk of intensive care
unit admission, mechanical ventilation or death is 2.4 times
higher (RR ¼ 2.4, 95% CI: 1.43e4.04).6 Structural and
immunologic-induced modifications are the two main
tobacco-related damages accounting for susceptibility
to infections. Peribronchiolar inflammation and fibrosis
facilitate pathogen adherence and potentially amplify pul-
monary inflammation.7 In addition, changes in humoral,
macrophage and cell-mediated immune response may
aggravate the immunosuppressive effect.8,9 It has been
postulated that prior tobacco-related lung damage,
including chronic obstructive pulmonary disease (COPD)
and lung cancer, additionally predispose to more severe
COVID-19 complications.5
While all types of malignancies seem to be associated
with high COVID-19 prevalence, morbidity and mortality,
lung cancer represents a specific scenario of cumulative risk
factors for COVID-19 complications, including older age,
significant cardiovascular and respiratory co-morbidities,
smoking-related lung damage, as well as the unavoidable
addition of treatment-related immune impairment or
suppression.10,11
Defective pulmonary architecture from mechanical tumor
obstruction or previous lung surgery may also predispose to
infection. Changes in the anatomy of airway and pulmonary
tissue lead to intratumoral and peritumoral microenviron-
ment alteration, which may secondarily affect immune cell
infiltration characterized by an increase in macrophages and
inflamation.12 The presence of macrophage infiltration in
lung tissue poses a higher risk for cytokine release. During
SARS-CoV-2 infection, massive cytokine release has been
postulated to be the major step in leading to the devel-
opment of ARDS.13,14 Considering that lung cancer patients
show similar clinical symptoms including cough, fever and
dyspnea with SARS-CoV-2 infection compared with other
individuals, an accurate COVID-19 screening model could
allow for early detection and potentially reduce the risk of
severe complication and mortality.
A significant proportion of lung cancer patients need
corticosteroids for prophylaxis, treatment and symptom
control related to cancer or COPD.15 It is well established
that steroids may reduce inflammation and immune
cellular activity, including lymphopenia and impaired T-cell
function. Corticosteroids are possibly deleterious in the
management of COVID-19 ARDS15 and they may mask
some of the early symptoms of SARS-CoV-2 infection,
arguing for routine SARS-CoV-2 testing in patients receiving
steroids.16Volume 31 - Issue 7 - 2020
Editorial Annals of OncologyTo date, many concerns are shared within the thoracic
oncology community on the predisposing risks of immu-
nosuppression by cancer therapy including chemotherapy,
immunotherapy and molecularly targeted therapy. These
concerns are supported by recent findings by Liang et al.
that surgery or chemotherapy within the month preceding
SARS-CoV-2 diagnosis was associated with higher risk of
complications.10 This may impose specific consideration on
the schedule and dose of cytotoxic chemotherapy for lung
cancer patients in epidemic areas such as the Lombardy
region in Italy.
While the impact of immune checkpoints inhibitors or
tyrosine kinase inhibitors on the risk and course of COVID-
19 remains unknown, radiological features of lung cancer or
related to these treatments may be characterized by
ground-glass opacities, mimicking COVID-19 radiological
characteristics. Recently, data about the higher sensitivity
of radiologic imaging compared with nasopharyngeal/
oropharyngeal swab are emerging,17 and considering that
lung cancer patients periodically undergo CT scans, an
emerging amount of COVID-19-suspicious imaging, even in
the absence of new symptoms, is likely to increase in the
next upcoming weeks.
In the era of COVID-19, the optimal management of patients
with lung cancer remains unknown and the oncology com-
munity should have increased awareness to prevent the
emergence of an increase in cancer-related and infectious
mortality. While suspending or delaying cancer treatment de-
livery seems logical in some cases, the risks/benefits and final
outcomes of these deviations remain to be measured.
With this in mind, a novel global registry (TER-
AVOLTdThoracic cancERs international coVid 19 cOLlabo-
raTion) is now in action, collecting data worldwide with the
objective of developing a tailored risk assessment strategy
for lung cancer patients.
Despite the current lack of robust data, it is essential to
establish an international consensus on testing for SARS-
CoV-2 in lung cancer patients, where the early identifica-
tion of SARS-CoV-2 may result in tailored management.
ESMO will soon publish proposals of treatment recom-
mendations in the era of COVID-19 on its website. In this
scenario, baseline SARS-CoV-2 testing for all patients
affected by lung cancer should be recommended. In addi-
tion, for those patients with a negative swab test and new
ground-glass opacities detected on CT scan, with or without
new respiratory symptoms, bronchoscopy should be
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